Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › colchicine

colchicine

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of colchicine

30 trials tracked of colchicine: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 2930 citations.

30Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 7 Phase 3 3 Phase 2 6 Phase 1 14
  1. Phase 3 Colchicine Cardiovascular Outcomes Trial (COLCOT) Completed · 2,930 cited
  2. Phase 4 Anti-inflammatory Effects of Colchicine in PCI Completed · 181 cited
  3. Phase 3 Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients Completed · 67 cited
  4. Phase 3 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout Completed · 31 cited
  5. Phase 4 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed
  6. Phase 4 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed
Show 24 more trials
  1. Phase 4 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed
  2. Phase 4 Drug Interaction Study of Colchicine and Theophylline Completed
  3. Phase 4 Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) Completed
  4. Phase 4 Anti-platelet Effects of Colchicine in Healthy Volunteers Completed
  5. Phase 2 Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients Completed
  6. Phase 2 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment Completed
  7. Phase 2 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma Completed
  8. Phase 2 A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) Completed
  9. Phase 2 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV Completed
  10. Phase 2 Inflammation and Coronary Endothelial Function Completed
  11. Phase 1 Drug-Food Interaction Study of Seville Orange Juice and Colchicine Completed
  12. Phase 1 Bioequivalence Study of Colchicine Tablets Completed
  13. Phase 1 A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice Completed
  14. Phase 1 Drug-Drug Interaction Study Between Colchicine and Diltiazem ER Completed
  15. Phase 1 Drug-Drug Interaction Study of Colchicine and Clarithromycin Completed
  16. Phase 1 Drug-Drug Interaction Between Colchicine and Verapamil ER Completed
  17. Phase 1 Drug-Drug Interaction Study Between Colchicine and Atorvastatin Completed
  18. Phase 1 Drug-Drug Interaction Between Colchicine and Ritonavir Completed
  19. Phase 1 Drug-Drug Interaction Study Between Colchicine and Ketoconazole Completed
  20. Phase 1 Drug-Drug Interaction Study Between Colchicine and Cyclosporine Completed
  21. Phase 1 Drug-Drug Interaction Study of Colchicine and Theophylline Completed
  22. Phase 1 Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study Completed
  23. Phase 1 A Pharmacokinetic Study of Colchicine With an Oral Contraceptive Completed
  24. Phase 1 Drug-Drug Interaction Study of Colchicine and Azithromycin Completed

Showing the 30 most-cited and recently-updated of 30 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Colchicine reduces major adverse cardiovascular events in coronary artery disease without increasing serious adverse events
Cardiology Meta-analysis
Colchicine reduces major adverse cardiovascular events in coronary artery disease without increasing serious adverse events Low-dose colchicine reduces heart attack risk for coronary artery disease patients
This systematic review and meta-analysis evaluated colchicine in patients with coronary artery disease and acute coronary syndromes. The ana…
A large analysis shows low-dose colchicine lowers major heart events for coronary artery disease patients without increasing serious risks, …
Jun 1, 2026
Narrative review outlines practical framework for combined lipid and anti-inflammatory therapy in coronary atherosclerosis
Cardiology Sys. Review
Narrative review outlines practical framework for combined lipid and anti-inflammatory therapy in coronary atherosclerosis Your Heart Has a Hidden Fire
This narrative review examines the role of colchicine and IL-1β inhibitors in patients with coronary atherosclerosis.
Doctors now know you must fight two enemies at once: the bad fats in your blood and the hidden inflammation that makes them dangerous.
Frontiers Apr 22, 2026
CHIP mutations increase cardiovascular risk and mortality in older adults independent of traditional factors
Cardiology Cohort
CHIP mutations increase cardiovascular risk and mortality in older adults independent of traditional factors Your Aging Blood Cells May Be Quietly Attacking Your Heart
This review synthesizes evidence regarding clonal hematopoiesis of indeterminate potential (CHIP) in individuals older than 70 years.
Aging blood cell mutations called CHIP quietly raise heart attack risk by fueling inflammation, affecting over 10% of adults over 70.
Frontiers Apr 13, 2026
Meta-analysis finds colchicine associated with reduced MACE in ASCVD, but heterogeneity is substantial
Cardiology Meta-analysis
Meta-analysis finds colchicine associated with reduced MACE in ASCVD, but heterogeneity is substantial Colchicine linked to fewer heart events in people with existing heart disease
A systematic review and meta-analysis of 5 RCTs (n=18,656 adults with established ASCVD) found colchicine was associated with reduced 4-poin…
A cautious statistical review of five trials found no solid proof that low-dose colchicine reduces major heart events in adults with existin…
medRxiv Apr 2, 2026
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients
Cardiology RCT
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients Can a cheap anti-inflammatory drug slow heart disease? It might help reduce plaque buildup
In the EKSTROM RCT (n=84), low-dose colchicine (0.5 mg/day) did not significantly reduce low attenuation plaque volume (median change 0.1 vs…
A cheap anti-inflammatory drug called colchicine may help slow total plaque buildup in arteries for people already managing stable heart dis…
Mar 30, 2026
Colchicine reduces arterial stiffness in high-risk T2D patients: RCT
Diabetes & Endocrinology RCT
Colchicine reduces arterial stiffness in high-risk T2D patients: RCT Could a common anti-inflammatory drug help protect the hearts of people with diabetes?
In a 26-week RCT of 100 high-risk patients with type 2 diabetes, colchicine 0.5 mg daily significantly reduced arterial stiffness (MAP-adjus…
A low-dose anti-inflammatory drug called colchicine may help keep arteries flexible and protect heart health in people with type 2 diabetes …
Mar 30, 2026
Meta-analysis: Colchicine reduces MACE by 17%, eMACE by 23% in ASCVD
Cardiology Meta-analysis
Meta-analysis: Colchicine reduces MACE by 17%, eMACE by 23% in ASCVD Can an old anti-inflammatory drug help prevent heart attacks? A review of 11 trials suggests it might
A meta-analysis of 11 trials (n=30,808) found low-dose colchicine was associated with a 17% reduction in MACE (RR 0.83, 95% CI 0.73-0.95; P=…
Adding a low-dose anti-inflammatory drug called colchicine to heart disease treatment lowers the risk of heart attacks and strokes by 17%.
Mar 30, 2026